Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

44132 reported adverse events

Drugs of this class: EFAVIRENZ NEVIRAPINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE ETRAVIRINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE DORAVIRINE DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

#	Side effect	Count
0	BONE DENSITY DECREASED	8652
1	CHRONIC KIDNEY DISEASE	5312
2	PAIN	4469
3	TOOTH LOSS	4365
4	RENAL INJURY	4351
5	RENAL FAILURE	4313
6	EMOTIONAL DISTRESS	4266
7	ANXIETY	4087
8	OSTEONECROSIS	3914
9	BONE LOSS	3913

See all common reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA	98	0.8909
1	HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION	145	0.6971
2	BONE DEMINERALISATION	256	0.5740
3	PINEALOBLASTOMA	49	0.5444
4	HIV-ASSOCIATED NEUROCOGNITIVE DISORDER	42	0.5185
5	TOOTH INJURY	1669	0.5154
6	CLOACAL EXSTROPHY	27	0.5000
7	BLADDER AGENESIS	32	0.4776
8	VIRAL MUTATION IDENTIFIED	1079	0.4397
9	VIROLOGIC FAILURE	1482	0.4226

See all enriched reactions for Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]